Posted by Michael Wonder on 18 Jan 2024
New orphan drug for a sub-type of acute myeloid leukaemia: G-BA sees significant additional benefit
18 January 2024 - Since July 2023, there has been one in Germany for patients who suffer from acute myeloid leukaemia with a specific mutation (IDH1-R132 mutation) but cannot be treated with intensive chemotherapy new treatment option: the active ingredient ivosidenib.
The Federal Joint Committee (G-BA) now classifies the additional benefit of the new active ingredient as “significant”.
